Ninety percent of acute lymphoblastic leukemia patients respond to investigational personalized cellular therapy, CTL019
by Bruce Sylvester: Researchers report that 90% of subjects with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies have achieved… read more.